A Phase 3, Long-Term, Open-Label Study of Difamilast Ointment to Evaluate Efficacy and Safety in Japanese Infants with Atopic Dermatitis

Abstract Introduction Difamilast is the first selective phosphodiesterase 4 inhibitor approved for atopic dermatitis (AD) in Japan. A phase 3, 52-week, open-label study was conducted to evaluate efficacy and safety of difamilast ointments in Japanese infants with AD aged 3 to < 24 months, because th...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hidehisa Saeki, Yukihiro Ohya, Naoko Baba, Tomomi Imamura, Daisuke Yokota, Hidetsugu Tsubouchi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2025-10-01
coleção:	Dermatology and Therapy
Assuntos:	Application Atopic dermatitis Difamilast Efficacy and safety Infants Ointment
Acesso em linha:	https://doi.org/10.1007/s13555-025-01581-1
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!